Showing posts with label antiplatelets. Show all posts
Showing posts with label antiplatelets. Show all posts

Monday, December 20, 2010

Clopidogrel- with or without PPI ??

Recently, concerns have been raised about the potential for PPIs to blunt the efficacy of clopidogrel.
Mechanism -  the interaction between the two is most likely due to competitive inhibition of the CYP2C19 isoenzyme trough which clopidogrel is metabolised to its active form.


A 2008 publication in JACC involving 124 pts. showed that omeprazole significantly reduced Clopidogrel's inhibitory effect on platelet P2Y12 measured by a method called Vasodilator stimulated vasoprotein(VASP) phosphorylation testing. A retrospective observational study(JAMA 2009) on 8000 patients on clopidogrel showed that concomitant use of clopidogrel and PPI after hospital discharge for ACS was associated with an increased risk of adverse outcomes than use of clopidogrel without PPI (adjusted odds ratio [AOR], 1.25; 95%confidence interval [CI],1.11-1.41)


This issue was addressed in the recent prospective randomized trial - COGENT ...published in NEJM . around 3700 patients taking clopidogrel and aspirin for cardiovascular reasons were randomly assigned to receive either omeprazole or placebo. The group on PPI showed a significant reduction in the number of GI bleed in 6 months ((1.1% with omeprazole and 2.9% with placebo (hazard ratio with omeprazole, 0.34, 95% confidence interval [CI], 0.18 to 0.63; P<0.001)). Both the groups had similar rates of adverse cardiovascular events. Also....subgroup analysis of trials like CREDO, TRITON  did not show any increase in cardiovascular event with PPI and clopidogrel. 
In spite of these data...FDA put a black box warning on the Clopidogrel-PPI interaction in Nov 2009.


The AHA/ ACC and American College of Cardiology jointly published a consensus statement 2 weeks ago based on the COGENT trial ---
 1.In patients with histories of upper GI bleeding and those at high risk for this complication (e.g., advanced age; concomitant use of warfarin, steroids, or nonsteroidal anti-inflammatory drugs; Helicobacter pylori infection), the benefits of PPI therapy probably outweigh the very small risk that PPI therapy will interfere with clopidogrel's efficacy. 
2.Patients at low risk for GI bleeding who require clopidogrel therapy should not receive concomitant PPIs.


There is some evidence that this interaction(if at all clinically significant) may not be a class effect. The authors of this study in Annals of Pharmacotherapy 2009 suggest that Omeprazole seems to interact more with clopidogrel's action in vitro..than Pantoprazole. May be ..until we get a solid answer from further trials......if PPI need to be used....lets use pantoprazole with clopidogrel (provided the insurance covers!!!!)

Friday, December 17, 2010

antiplatelets after ICH - Is it adding insult to injury??

Antiplatelets are an indispensible tool in managing atherosclerotic disease (CVS & stroke especially). The main problem with these agents have been the risk of bleeding (mostly GI bleeding & intracranial bleed). They definitely pose a bigger risk for intracerebral bleed(ICH) than patients not on antiplatelets. But since benefits outweigh this risk...we have patients on antiplatelets all the time!
This leads to 2 questions!!


1. Do patients with ICH do worse if they were on antiplatelets Vs not been on antiplatelets before the event?
It appears that patients who are on antiplatelets ,and have an ICH are 3 times more likely to die at 30 days than patients with ICH who were not on an antiplatelet.(Stroke 2007). A metanalysis of 25 studies published in (Neurology.Sept 2010) also supported the fact that prior antiplatelet use independently predicted worse mortality in case of ICH.


2. Can antiplatelets be started again in patients after an ICH. and if so..when?
The answer is YES(provided they have a compelling reason to use). The answer came up with the recent study from UK..published in Stroke.Oct 2010. 120 patients out of 417 pts who survived a ICH were prescribed antipletelet therapy. The median time from discharge to antiplatelet use was 14.8 months (range, 2 days–7.5 years).Among all survivors, there were 14 recurrent ICH, 29 subsequent ischemic strokes , and 40 subsequent ischemic strokes or myocardial infarctions .Hazard ratios associated with antiplatelet exposure were 1.07 (95% CI, 0.24–4.84) for recurrent ICH, 0.23 (95% CI, 0.03–1.68) for ischemic stroke, and 0.72 (95% CI, 0.25–2.02) for ischemic strokes or myocardial infarction. So, antiplatelet use was not associated with worse outcome.....and in fact MI & ischemic stroke were more common in this group than ICH.


A review published in Nature Neurology 2006...also concluded that antiplatelets after ICH do not increase the risk of a second ICH.
Based on this recent study....a better time to start antiplatelets would be  between 6 months to 1 year ...again ..provided there is a strong indication to restart them (coronary stents, A fib etc)

Wednesday, September 29, 2010

combination of Aspirin,Plavix & Warfarin - how bad or how good?

I am sure you had come across those patients who had been on aspirin & warfarin ..or...plavix & warfarin...or rarely all three (either intentionally or by mistake!!). Well...a patient with CAD might benefit more from a antiplatelet...but may need warfarin for A.fib ....will he benefit from both? A recent article from Arch of Int Medicine tried to address these issues by calculating the risk of bleeding associated with each combination.
Lets look at the risk of stoke with A fib at 1 year...so the numbers from the above study would make more sense.

Risk of stroke with A fib - commonly assessed with CHADS2 score
CHADS score of 0,1,2,3,4,5 & 6 carries a 1 year stroke risk of ..roughly 2%,3%, 4%, 6%, 8%, 12% & 18% respectively.So we usually start treatment to prevent this thromboembolic risk by starting them on either antiplatelets or warfarin. This question about warfarin or no warfarin always pops up when we see a patient with A fib.

Now lets see the numbers from the above study where they looked at a cohort of 82,000 patients discharged with a diagnosis of Atrial fibrillation. During a follow up period of 3 years ..11%(13,000 pts) had a fatal or non-fatal bleeding.Having warfarin as the standard ..the hazard ratio for the above end point is as follows
For Aspirin alone - 0.93
for plavix alone - 1.06
for aspirin + plavix - 1.66
for aspirin + warfarin - 1.83
for plavix + warfarin - 3.08
for aspirin +plavix+warfarin - 3.70

Clearly this was something that was expected ..based on previous studies. The crude incidence rate of bleeding was 13% for plavix +warfarin, and 15% for triple therapy. So having these numbers ...gives a better idea for making a risk-benefit decision !! ...So ..whoever your pt is....aspirin+plavix+warfarin seems to be a bad combination!

Monday, August 2, 2010

Stroke and antiplatelets - Aspirin or dipyridamole or plavix?


Todays morning report was about a 63 yo female presenting with slurred speech and some left sided weakness while she was on Aspirin. MRI showed a brainstem infarct. What would be her antiplatelet mnagement?


lets look at some evidence for secondary prevention.There are 2 studies we can quickly look at


1.European Stroke Prevention study (ESPS2) - nearly 7000 patients with TIA/stroke were randomised to ASA or Dipyridamole or both. Primary end point was stroke/death. follw up for 2 years showed a similar risk reduction (13%) in both ASA and dipyridamole groups. The aggrenox group had a 37% risk reduction. Another study ,ESPIRIT in 2006 also showed same benifit.


2. PROFESS trial - this was published in NEJM recently. 20 332 patients from 695 sites in 35 countries. All had had a noncardioembolic ischemic stroke within the previous 120 days.They were randomized to receive Aggrenox bid or clopidogrel (75 mg) once daily.primary outcome was recurrent stroke. There was no difference between the two agents, except for a nonsignificant increase in major hemorrhagic events(4.1% Vs 3.6%). Conclusion- Plavix is not inferior to aggrenox in secondary prevention of stroke.


These two studies (and a few other studies like MATCH which compared ASA with ASA & plavix) made changes to the AHA guidelines for stroke.


The current recommendation is that aggrenox is superior to ASA alone, but all 3 agents(ASA, aggrenox, Plavix) can be used as first line antiplatelets in patients with non carioembolic stroke.